216 related articles for article (PubMed ID: 31071376)
1. [Nanotechnology-mediated immunochemotherapy with Ingenol-3-Mebutate for Systematic Anti-tumor Effects].
Yu M; Zhao M; Yu R; Chu S; Xu J; Xia M; Wang C
J Control Release; 2019 Jun; 304():242-258. PubMed ID: 31071376
[TBL] [Abstract][Full Text] [Related]
2. Sequential receptor-mediated mixed-charge nanomedicine to target pancreatic cancer, inducing immunogenic cell death and reshaping the tumor microenvironment.
Shen J; Sun C; Wang Z; Chu Z; Liu C; Xu X; Xia M; Zhao M; Wang C
Int J Pharm; 2021 May; 601():120553. PubMed ID: 33794325
[TBL] [Abstract][Full Text] [Related]
3. Ingenol-3-Angelate Suppresses Growth of Melanoma Cells and Skin Tumor Development by Downregulation of NF-κB-Cox2 Signaling.
Wang D; Liu P
Med Sci Monit; 2018 Jan; 24():486-502. PubMed ID: 29368698
[TBL] [Abstract][Full Text] [Related]
4. RasGRPs are targets of the anti-cancer agent ingenol-3-angelate.
Song X; Lopez-Campistrous A; Sun L; Dower NA; Kedei N; Yang J; Kelsey JS; Lewin NE; Esch TE; Blumberg PM; Stone JC
PLoS One; 2013; 8(8):e72331. PubMed ID: 23991094
[TBL] [Abstract][Full Text] [Related]
5. Exploring the use of ingenol mebutate to prevent non-melanoma skin cancer.
Erlendsson AM
Dan Med J; 2017 Nov; 64(11):. PubMed ID: 29115209
[TBL] [Abstract][Full Text] [Related]
6. Characterization of the interaction of ingenol 3-angelate with protein kinase C.
Kedei N; Lundberg DJ; Toth A; Welburn P; Garfield SH; Blumberg PM
Cancer Res; 2004 May; 64(9):3243-55. PubMed ID: 15126366
[TBL] [Abstract][Full Text] [Related]
7. IL-1 Contributes to the Anti-Cancer Efficacy of Ingenol Mebutate.
Le TT; Skak K; Schroder K; Schroder WA; Boyle GM; Pierce CJ; Suhrbier A
PLoS One; 2016; 11(4):e0153975. PubMed ID: 27100888
[TBL] [Abstract][Full Text] [Related]
8. Cascade targeting codelivery of ingenol-3-angelate and doxorubicin for enhancing cancer chemoimmunotherapy through synergistic effects in prostate cancer.
Wang Z; Sun C; Wu H; Xie J; Zhang T; Li Y; Xu X; Wang P; Wang C
Mater Today Bio; 2022 Jan; 13():100189. PubMed ID: 34977528
[TBL] [Abstract][Full Text] [Related]
9. Molecular-Targeted Immunotherapeutic Strategy for Melanoma via Dual-Targeting Nanoparticles Delivering Small Interfering RNA to Tumor-Associated Macrophages.
Qian Y; Qiao S; Dai Y; Xu G; Dai B; Lu L; Yu X; Luo Q; Zhang Z
ACS Nano; 2017 Sep; 11(9):9536-9549. PubMed ID: 28858473
[TBL] [Abstract][Full Text] [Related]
10. Co-delivery of Doxorubicin and Interferon-γ by Thermosensitive Nanoparticles for Cancer Immunochemotherapy.
Yin Y; Hu Q; Xu C; Qiao Q; Qin X; Song Q; Peng Y; Zhao Y; Zhang Z
Mol Pharm; 2018 Sep; 15(9):4161-4172. PubMed ID: 30011369
[TBL] [Abstract][Full Text] [Related]
11. Target delivery selective CSF-1R inhibitor to tumor-associated macrophages via erythrocyte-cancer cell hybrid membrane camouflaged pH-responsive copolymer micelle for cancer immunotherapy.
Wang Y; Luan Z; Zhao C; Bai C; Yang K
Eur J Pharm Sci; 2020 Jan; 142():105136. PubMed ID: 31704343
[TBL] [Abstract][Full Text] [Related]
12. Molecular immunological approaches to biotherapy of human cancers--a review, hypothesis and implications.
Becker Y
Anticancer Res; 2006; 26(2A):1113-34. PubMed ID: 16619514
[TBL] [Abstract][Full Text] [Related]
13. Inhibition of Cancer Angiogenesis Using Triptolide Nanoparticles.
Wang C; Shan Y; Yang J; Xu X; Zhuang B; Fan Y; Xu W
J Biomed Nanotechnol; 2015 May; 11(5):805-15. PubMed ID: 26349393
[TBL] [Abstract][Full Text] [Related]
14. Anti-tumour and immuno-modulation effects of triptolide-loaded polymeric micelles.
Xu L; Chen H; Xu H; Yang X
Eur J Pharm Biopharm; 2008 Nov; 70(3):741-8. PubMed ID: 18761405
[TBL] [Abstract][Full Text] [Related]
15. Transfer of IFNgamma-depleted CD4(+) T cells together with CD8(+) T cells leads to rejection of murine kidney sarcoma in mice.
Klugewitz K; Scheffold A; Radbruch A; Hamann A
Int J Cancer; 2000 Sep; 87(5):673-9. PubMed ID: 10925361
[TBL] [Abstract][Full Text] [Related]
16. Intratumoral delivery of dendritic cells engineered to secrete both interleukin (IL)-12 and IL-18 effectively treats local and distant disease in association with broadly reactive Tc1-type immunity.
Tatsumi T; Huang J; Gooding WE; Gambotto A; Robbins PD; Vujanovic NL; Alber SM; Watkins SC; Okada H; Storkus WJ
Cancer Res; 2003 Oct; 63(19):6378-86. PubMed ID: 14559827
[TBL] [Abstract][Full Text] [Related]
17. The effect of Gd@C82(OH)22 nanoparticles on the release of Th1/Th2 cytokines and induction of TNF-alpha mediated cellular immunity.
Liu Y; Jiao F; Qiu Y; Li W; Lao F; Zhou G; Sun B; Xing G; Dong J; Zhao Y; Chai Z; Chen C
Biomaterials; 2009 Aug; 30(23-24):3934-45. PubMed ID: 19403166
[TBL] [Abstract][Full Text] [Related]
18. In vivo stepwise immunomodulation using chitosan nanoparticles as a platform nanotechnology for cancer immunotherapy.
Han HD; Byeon Y; Jang JH; Jeon HN; Kim GH; Kim MG; Pack CG; Kang TH; Jung ID; Lim YT; Lee YJ; Lee JW; Shin BC; Ahn HJ; Sood AK; Park YM
Sci Rep; 2016 Dec; 6():38348. PubMed ID: 27910914
[TBL] [Abstract][Full Text] [Related]
19. Tumor-targeted delivery of sunitinib base enhances vaccine therapy for advanced melanoma by remodeling the tumor microenvironment.
Huo M; Zhao Y; Satterlee AB; Wang Y; Xu Y; Huang L
J Control Release; 2017 Jan; 245():81-94. PubMed ID: 27863995
[TBL] [Abstract][Full Text] [Related]
20. Cyclophosphamide enhances the antitumor efficacy of adoptively transferred immune cells through the induction of cytokine expression, B-cell and T-cell homeostatic proliferation, and specific tumor infiltration.
Bracci L; Moschella F; Sestili P; La Sorsa V; Valentini M; Canini I; Baccarini S; Maccari S; Ramoni C; Belardelli F; Proietti E
Clin Cancer Res; 2007 Jan; 13(2 Pt 1):644-53. PubMed ID: 17255288
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
